【Nature】The big move!

The first FDA-approved gene therapy is a live drug: Immune cells extracted from cancer patients are engineered to target tumor cells

The research paper, published March 16 in Nature, titled "A genome-scale screen for synthetic drivers of T cell proliferation," describes the discovery of a synthetic genetic program capable of reorganizing T cells to make them more Effectively find and fight cancer cells

https://doi.

T cells have previously been engineered to target specific types of tumors primarily through careful selection of cancer- or tissue-specific proteins (antigens)

LTBR-engineered CAR-T cells, conventional CAR-T cells mixed with CD19+ blood cancer cells

Dr.

By combining the screened modifier genes with existing CARs, the researchers were able to engineer T cells to eliminate tumor cells more efficiently

"Our goal was to take existing immunotherapies and make them even better

The new method they developed, OverCITE-seq, allows researchers to test the effect of different modifier genes on the cellular state of T cells, including the expression of each gene, the proteins that decorate the cell surface, and the unique T cell receptors (clones) expressed by each cell.

"The most exciting thing is that LTBR and other high-ranking genes improved antigen-specific responses of CAR-T cells and γδ T cells

T cell and immunotherapy expert Andrew Sewell, Ph.

Since newly characterized modifier genes like LTBR can be combined with already approved CAR-T therapies, this research has great potential from experimental to clinical to improve outcomes for cancer patients around the world

References:

This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans